During the corresponding time, Artivion Inc recorded a revenue increase by 17.11 % year on year, sequentially revenue fell by -2.28 %. While revenue at the Artivion Inc 's corporate clients
Artivion Inc's Comment on Sales, Marketing and Customers
The company supplies human cardiac tissues, including CryoValve SGPV and CryoPatch SG, to implanting institutions across the United States under FDA 510(k) clearance. It also ships limited quantities of tissues to Canada and other countries through special access programs. Its vascular preservation services provide human vascular tissues such as saphenous veins, aortoiliac arteries, and femoral veins and arteries for vascular reconstructions, including peripheral bypass, hemodialysis access, and treatment of aortic infections. These human tissues are used as alternatives to synthetic and bioprosthetic options and are preferred for infection treatment and their similarity to patient tissue. Competitors in human vascular tissue preservation include LifeNet and LeMaitre, while synthetic and bioprosthetic competitors include Gore, BD, LeMaitre, LifeNet, and Maquet. The company also offers PhotoFix, a bovine pericardial patch with FDA 510(k) clearance and CE Mark, indicated for intracardiac repair, great vessel repair, suture line buttressing, pericardial closure, and vascular repair and reconstruction.
Customers and markets identified in company filings include Abbott Laboratories, Anteris Technologies, Baxter, BD, Corcym, Edwards Lifesciences, Gore, LeMaitre, LifeNet, Maquet, and Medtronic.
Artivion Inc’s Comment on Sales, Marketing and Customers
The company supplies human cardiac tissues, including CryoValve SGPV and CryoPatch SG, to implanting institutions across the United States under FDA 510(k) clearance. It also ships limited quantities of tissues to Canada and other countries through special access programs. Its vascular preservation services provide human vascular tissues such as saphenous veins, aortoiliac arteries, and femoral veins and arteries for vascular reconstructions, including peripheral bypass, hemodialysis access, and treatment of aortic infections. These human tissues are used as alternatives to synthetic and bioprosthetic options and are preferred for infection treatment and their similarity to patient tissue. Competitors in human vascular tissue preservation include LifeNet and LeMaitre, while synthetic and bioprosthetic competitors include Gore, BD, LeMaitre, LifeNet, and Maquet. The company also offers PhotoFix, a bovine pericardial patch with FDA 510(k) clearance and CE Mark, indicated for intracardiac repair, great vessel repair, suture line buttressing, pericardial closure, and vascular repair and reconstruction.
Customers and markets identified in company filings include Abbott Laboratories, Anteris Technologies, Baxter, BD, Corcym, Edwards Lifesciences, Gore, LeMaitre, LifeNet, Maquet, and Medtronic.
Sources:
Artivion Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Artivion Inc’s corporate clients.
For your research, we’ve provided 9 tables on Artivion Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
104.83 %